Skip to: Content
Skip to: Site Navigation
Skip to: Search

FRIDAY, NOVEMBER 27, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter


0

Popular Cancer Drug Is Iffy and Expensive

Widely prescribed Avastin doesn't prolong life, studies say

Share

(Newser) – Avastin is one of the most widely prescribed cancer drugs in the world, but it might not work, the New York Times reports. The drug, made by Genentech, brings in about $2.3 billion a year in the US alone, but recent trials have shown that though the drug shrinks tumors in sufferers of colon, breast, and lung cancer, it offers little extension of life.

Further complicating the issue, Avastin is routinely prescribed for cancers for which it's not recommended. But some doctors can’t shake that humanitarian impulse, as Avastin patients have reported a positive quality-of-life change, Medicare dollars be damned. “I can’t say, ‘Let’s not use Avastin; it’s a very expensive drug and I am worried about the cost to society,’" said one physician.

The Genentech Inc. headquarters are seen in South San Francisco, Calif.
The Genentech Inc. headquarters are seen in South San Francisco, Calif.   (AP Photo/Paul Sakuma, file)
Exterior view of Genentech Inc.
Exterior view of Genentech Inc.   (AP Photo/Paul Sakuma)
Loaded boxes are seen in the stockroom of Swiss pharmaceutical company Roche.
Loaded boxes are seen in the stockroom of Swiss pharmaceutical company Roche.   (AP Photo/Keystone, Martin Ruetschi)
Medicine used in the treatment of advanced lung cancer.
Medicine used in the treatment of advanced lung cancer.   (AP Photo/Javier Galeano)
« Prev« Prev | Next »Next » Slideshow
0 comments
VIEWING:
 
LEAVE A
COMMENT
Comment Policy
Facebook ConnectPost this comment to Facebook?

After connecting you will have the option to post your comment on your Facebook profile.